Antimicrobial resistance refers to the phenomenon where microorganisms, including bacteria and fungi, develop the ability to withstand the effects of medications designed to eliminate them. This resistance poses a significant challenge in the treatment of infections and, in severe cases, can lead to fatalities.
The primary classes of drugs associated with antibiotic resistance include beta-lactam antibiotics, cephalosporins, quinolone antibiotics, macrolide antibiotics, tetracyclines, oxazolidinones, and others. Beta-lactam antibiotics, characterized by a beta-lactam ring in their chemical structure, work by preventing the construction of bacterial cell walls. They achieve this by covalently binding to crucial penicillin-binding proteins (PBPs), inhibiting the growth of organisms. Pathogens affected by these drugs include Staphylococcus aureus, Staphylococcus pneumonia, Neisseria gonorrhoeae, Enterococcus faecium, Escherichia coli, Klebsiella pneumonia, Shigella, Clostridium difficile, among others. These drugs are employed in the treatment of various diseases such as urinary tract infections, intra-abdominal infections, bloodstream infections, and Clostridium difficile infections. The mechanisms of action encompass protein synthesis inhibitors, cell wall synthesis inhibitors, RNA synthesis inhibitors, DNA synthesis inhibitors, and others. These drugs are utilized by diverse end-users, including hospitals, homecare, specialty clinics, and more.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The antibiotic resistance market research report is one of a series of new reports from The Business Research Company that provides antibiotic resistance market statistics, including the antibiotic resistance industry global market size, regional shares, competitors with an antibiotic resistance market share, detailed antibiotic resistance market segments, market trends, and opportunities, and any further data you may need to thrive in the antibiotic resistance industry. This antibiotic resistance market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The antibiotic resistance market size has grown strongly in recent years. It will grow from $12.21 billion in 2024 to $12.85 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to lack of new antibiotics, misuse and overuse of antimicrobials in humans, animals, and plants, highly contaminated waste effluents, low vaccination rates, lack of diagnostic tools.
The antibiotic resistance market size is expected to see strong growth in the next few years. It will grow to $16.9 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to incomplete treatment courses, globalization and travel, poor infection prevention and control, self-medication, cross-species transmission, high population density. Major trends in the forecast period include technological innovations in drug delivery, global collaboration for surveillance, expanding role of artificial intelligence, surge in novel therapies.
The forecast of 7.1% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. infectious disease management by inflating prices of next-generation antibiotics and rapid susceptibility testing panels developed in the UK and Sweden, resulting in prolonged empiric treatment and higher antimicrobial stewardship program costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing prevalence of drug-resistant infections is expected to drive the growth of the antibiotic-resistance market in the future. Drug-resistant infections are caused by bacteria that have developed resistance, making the infections significantly harder or even impossible to treat. Antimicrobial resistance drugs aid in treating various drug-resistant infections by improving antibiotic treatment outcomes for both target and non-target pathogens, depending on the specifics of resistance mechanisms and microbiome community interactions. For example, in November 2023, a report from the UK Health Security Agency, a government body, estimated that around 58,224 individuals in England had an antibiotic-resistant infection in 2022, reflecting a 4% rise from the 55,792 cases recorded in 2021. Thus, the increasing prevalence of drug-resistant infections is driving the growth of the antibiotic-resistance market.
The escalation in healthcare expenditure is poised to fuel the growth trajectory of the antibiotic resistance market. Healthcare expenditure denotes the cumulative financial resources invested in healthcare-related goods and services within a specified timeframe. Increased healthcare spending plays a pivotal role in propelling the antibiotic resistance market by fostering heightened research, development, and adoption of innovative treatments to counter the challenges posed by antibiotic-resistant infections. Notably, as per the 2021-2030 National Health Expenditure (NHE) report released by the Centers for Medicare & Medicaid Services in March 2022, projections indicate an estimated annual growth rate of 5.1% in national health spending between 2021 and 2030, reaching nearly $6.8 trillion. Moreover, the anticipated annual growth rates of 7.2% for Medicare spending and 5.6% for Medicaid spending from 2021 to 2030 underscore the substantial contribution of growing healthcare expenditure to the expansion of the antibiotic resistance market.
The antibiotic resistance market is witnessing a prominent trend centered on product innovations. Key players within this market are dedicated to pioneering innovative products to solidify their market presence. For instance, in January 2023, Alkem Laboratories Limited, an India-based pharmaceutical firm, introduced Zidavi. This novel antibiotic, a combination of ceftazidime and avibactam, addresses multi-drug resistant (MDR) infections, ensuring accessibility, affordability, and availability for critically ill patients. Zidavi, available in sterile powdered concentrate for reconstitution, offers a distinctive solution for treating infections caused by MDR gram-negative pathogens. Its formulation in single-dose vials provides an effective alternative for treating hospital-acquired pneumonia (HAP) and severe intra-abdominal infections (IAIs) linked to meropenem and colistin resistance.
Major enterprises in the antibiotic resistance market are strategically fostering partnerships to innovate and create the next generation of antimicrobial agents alongside practical diagnostics in the fight against Antimicrobial Resistance (AMR). These strategic collaborations involve leveraging complementary strengths and resources to achieve mutual success. For example, in July 2022, Boehringer Ingelheim, a Germany-based pharmaceutical company, and Evotec SE, a German biotechnology firm, joined forces with bioMerieux, a France-based diagnostic solutions provider. This partnership resulted in the formation of Aurobac Therapeutics SAS, aiming to pioneer a novel precision medicine strategy spanning diagnosis to treatment by harnessing the collective expertise of the founding companies. Their collaborative efforts aim to develop innovative antimicrobials coupled with effective diagnostics to counter the challenge posed by Antimicrobial Resistance (AMR).
In July 2022, Innoviva Inc., a pharmaceutical company based in the United States, successfully acquired Entasis Therapeutics Holdings Inc for an undisclosed sum. This strategic acquisition is designed to enhance Innoviva Inc's product portfolio focused on addressing multidrug-resistant gram-negative bacteria, providing a competitive edge in the market. Entasis Therapeutics Holdings Inc., a US-based company, specializes in the development of innovative antibacterial solutions for the treatment of severe bacterial infections resistant to conventional drugs.
Major companies operating in the antibiotic resistance market include Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, AbbVie Inc., Novartis AG, Merck and Co. Inc., Bristol-Myers Squibb, Sanofi S.A., Thermo Fisher Scientific Inc, AstraZeneca, GlaxoSmithKline Plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Astellas Pharma, Daiichi Sankyo, Chugai Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Bio-Rad Laboratories Inc, Eppendorf Corporation, Takara Bio Inc, Wockhardt Ltd., Paratek Pharmaceuticals Inc., Basilea Pharmaceutica Ltd., Theravance Biopharma Inc., Nabriva Therapeutics Plc, Seres Therapeutics Inc, Armata Pharmaceuticals Inc.
North America was the largest region in the antibiotic resistance market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibiotic resistance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the antibiotic resistance market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The antibiotic resistance market consists of sales of antibiotic drug classes such as carbapenems, glycopeptide antibiotics, penicillin, fluoroquinolones, trimethoprim-sulfamethoxazole, lincosamides, aminoglycosides, polymyxins, and nitroimidazoles. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Antibiotic Resistance Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on antibiotic resistance market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for antibiotic resistance ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The antibiotic resistance market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Drug Class: Beta Lactum Antibiotic; Cephalosporins; Quinolones Antibiotics; Macrolide Antibiotics; Tetracyclines; Oxazolidinones; Other Drug Classes
- 2) By Pathogen: Staphylococcus Aureus; Staphylococcus Pneumonia; Neisseria Gonorrhoeae; Enterococcus Faecium; Escherichia Coli; Klebsiella Pneumonia; Shigella; Clostridium Difficile; Other Pathogens
- 3) By Disease Type: Urinary Tract Infection; Intra-Abdominal Infection; Blood Stream infections; Clostridium Difficile Infections; Other Disease Types
- 4) By Mechanism Of Action: Protein Synthesis Inhibitors; Cell Wall Synthesis Inhibitors; RNA Synthesis Inhibitors; DNA Synthesis Inhibitors; Other Mechanism Of Actions
- 5) By End Users: Hospitals; Homecare; Specialty Clinics; Other End-users
- Subsegments:
- 1) By Beta Lactam Antibiotics: Penicillins; Cephalosporins; Carbapenems; Monobactams
- 2) By Cephalosporins: First-generation; Second-generation; Third-generation; Fourth-generation
- 3) By Quinolones Antibiotics: Fluoroquinolones; Other Quinolones
- 4) By Macrolide Antibiotics: Erythromycin; Azithromycin; Clarithromycin
- 5) By Tetracyclines: Doxycycline; Minocycline; Tetracycline
- 6) By Oxazolidinones: Linezolid; Tedizolid
- 7) By Other Drug Classes: Glycopeptides; Lipopeptides; Streptogramins; Polymyxins
- Companies Mentioned: Pfizer Inc.; Johnson and Johnson; F. Hoffmann-La Roche Ltd; AbbVie Inc.; Novartis AG; Merck and Co. Inc.; Bristol-Myers Squibb; Sanofi S.A.; Thermo Fisher Scientific Inc; AstraZeneca; GlaxoSmithKline Plc; Eli Lilly and Company; Boehringer Ingelheim International GmbH; Astellas Pharma; Daiichi Sankyo; Chugai Pharmaceutical Co. Ltd.; Teva Pharmaceutical Industries Ltd.; Bio-Rad Laboratories Inc; Eppendorf Corporation; Takara Bio Inc; Wockhardt Ltd.; Paratek Pharmaceuticals Inc.; Basilea Pharmaceutica Ltd.; Theravance Biopharma Inc.; Nabriva Therapeutics Plc; Seres Therapeutics Inc; Armata Pharmaceuticals Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Antibiotic Resistance Market Characteristics
3. Antibiotic Resistance Market Trends And Strategies
4. Antibiotic Resistance Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Antibiotic Resistance Growth Analysis And Strategic Analysis Framework
- 5.1. Global Antibiotic Resistance PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Antibiotic Resistance Market Growth Rate Analysis
- 5.4. Global Antibiotic Resistance Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Antibiotic Resistance Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Antibiotic Resistance Total Addressable Market (TAM)
6. Antibiotic Resistance Market Segmentation
- 6.1. Global Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Beta Lactum Antibiotic
- Cephalosporins
- Quinolones Antibiotics
- Macrolide Antibiotics
- Tetracyclines
- Oxazolidinones
- Other Drug Classes
- 6.2. Global Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Staphylococcus Aureus
- Staphylococcus Pneumonia
- Neisseria Gonorrhoeae
- Enterococcus Faecium
- Escherichia Coli
- Klebsiella Pneumonia
- Shigella
- Clostridium Difficile
- 6.3. Global Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Urinary Tract Infection
- Intra-Abdominal Infection
- Blood Stream infections
- Clostridium Difficile Infections
- Other Disease Types
- 6.4. Global Antibiotic Resistance Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Protein Synthesis Inhibitors
- Cell Wall Synthesis Inhibitors
- RNA Synthesis Inhibitors
- DNA Synthesis Inhibitors
- Other Mechanism Of Actions
- 6.5. Global Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Homecare
- Specialty Clinics
- Other End-users
- 6.6. Global Antibiotic Resistance Market, Sub-Segmentation Of Beta Lactam Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Penicillins
- Cephalosporins
- Carbapenems
- Monobactams
- 6.7. Global Antibiotic Resistance Market, Sub-Segmentation Of Cephalosporins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- First-generation
- Second-generation
- Third-generation
- Fourth-generation
- 6.8. Global Antibiotic Resistance Market, Sub-Segmentation Of Quinolones Antibiotics,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Fluoroquinolones
- Other Quinolones
- 6.9. Global Antibiotic Resistance Market, Sub-Segmentation Of Macrolide Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Erythromycin
- Azithromycin
- Clarithromycin
- 6.10. Global Antibiotic Resistance Market, Sub-Segmentation Of Tetracyclines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Doxycycline
- Minocycline
- Tetracycline
- 6.11. Global Antibiotic Resistance Market, Sub-Segmentation Of Oxazolidinones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Linezolid
- Tedizolid
- 6.12. Global Antibiotic Resistance Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Glycopeptides
- Lipopeptides
- Streptogramins
- Polymyxins
7. Antibiotic Resistance Market Regional And Country Analysis
- 7.1. Global Antibiotic Resistance Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Antibiotic Resistance Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Antibiotic Resistance Market
- 8.1. Asia-Pacific Antibiotic Resistance Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Antibiotic Resistance Market
- 9.1. China Antibiotic Resistance Market Overview
- 9.2. China Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Antibiotic Resistance Market
- 10.1. India Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Antibiotic Resistance Market
- 11.1. Japan Antibiotic Resistance Market Overview
- 11.2. Japan Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Antibiotic Resistance Market
- 12.1. Australia Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Antibiotic Resistance Market
- 13.1. Indonesia Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Antibiotic Resistance Market
- 14.1. South Korea Antibiotic Resistance Market Overview
- 14.2. South Korea Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Antibiotic Resistance Market
- 15.1. Western Europe Antibiotic Resistance Market Overview
- 15.2. Western Europe Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Antibiotic Resistance Market
- 16.1. UK Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Antibiotic Resistance Market
- 17.1. Germany Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Antibiotic Resistance Market
- 18.1. France Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Antibiotic Resistance Market
- 19.1. Italy Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Antibiotic Resistance Market
- 20.1. Spain Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Antibiotic Resistance Market
- 21.1. Eastern Europe Antibiotic Resistance Market Overview
- 21.2. Eastern Europe Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Antibiotic Resistance Market
- 22.1. Russia Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Antibiotic Resistance Market
- 23.1. North America Antibiotic Resistance Market Overview
- 23.2. North America Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Antibiotic Resistance Market
- 24.1. USA Antibiotic Resistance Market Overview
- 24.2. USA Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Antibiotic Resistance Market
- 25.1. Canada Antibiotic Resistance Market Overview
- 25.2. Canada Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Antibiotic Resistance Market
- 26.1. South America Antibiotic Resistance Market Overview
- 26.2. South America Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Antibiotic Resistance Market
- 27.1. Brazil Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Antibiotic Resistance Market
- 28.1. Middle East Antibiotic Resistance Market Overview
- 28.2. Middle East Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Antibiotic Resistance Market
- 29.1. Africa Antibiotic Resistance Market Overview
- 29.2. Africa Antibiotic Resistance Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Antibiotic Resistance Market Competitive Landscape And Company Profiles
- 30.1. Antibiotic Resistance Market Competitive Landscape
- 30.2. Antibiotic Resistance Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
31. Antibiotic Resistance Market Other Major And Innovative Companies
- 31.1. Merck and Co. Inc.
- 31.2. Bristol-Myers Squibb
- 31.3. Sanofi S.A.
- 31.4. Thermo Fisher Scientific Inc
- 31.5. AstraZeneca
- 31.6. GlaxoSmithKline Plc
- 31.7. Eli Lilly and Company
- 31.8. Boehringer Ingelheim International GmbH
- 31.9. Astellas Pharma
- 31.10. Daiichi Sankyo
- 31.11. Chugai Pharmaceutical Co. Ltd.
- 31.12. Teva Pharmaceutical Industries Ltd.
- 31.13. Bio-Rad Laboratories Inc
- 31.14. Eppendorf Corporation
- 31.15. Takara Bio Inc
32. Global Antibiotic Resistance Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Antibiotic Resistance Market
34. Recent Developments In The Antibiotic Resistance Market
35. Antibiotic Resistance Market High Potential Countries, Segments and Strategies
- 35.1 Antibiotic Resistance Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Antibiotic Resistance Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Antibiotic Resistance Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
